DK0744950T3 - Middel til forhindring og behandling af thromboxan A2-medierede sygdomme - Google Patents

Middel til forhindring og behandling af thromboxan A2-medierede sygdomme

Info

Publication number: DK0744950T3
Authority: DK; Denmark
Prior art keywords: txa2; mediated diseases; pct; agent; treatment
Prior art date: 1994-02-22

Application number

DK95909122T

Other languages

English (en)

Inventor

Ruriko Ikegawa

Teruaki Imada

Norifumi Nakamura

Keizo Tanikawa

Nobutomo Tsuruzoe

Original Assignee

Nissan Chemical Ind Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-22

Filing date

1995-02-20

Publication date

2004-10-25

1995-02-20 Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd

2004-10-25 Application granted granted Critical

2004-10-25 Publication of DK0744950T3 publication Critical patent/DK0744950T3/da

Links

201000010099 disease Diseases 0.000 title abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
230000001404 mediated effect Effects 0.000 title abstract 4
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 title abstract 4
238000011282 treatment Methods 0.000 title abstract 3
230000002265 prevention Effects 0.000 title 1
102000003960 Ligases Human genes 0.000 abstract 3
108090000364 Ligases Proteins 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
238000011321 prophylaxis Methods 0.000 abstract 2
-1 pyridazinone compound Chemical class 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Confectionery (AREA)
Medicines Containing Plant Substances (AREA)
Pyridine Compounds (AREA)

DK95909122T 1994-02-22 1995-02-20 Middel til forhindring og behandling af thromboxan A2-medierede sygdomme DK0744950T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2455694		1994-02-22
PCT/JP1995/000244 WO1995022329A1 (en)	1994-02-22	1995-02-20	Agent for prophylaxis and treatment of thromboxane a2-mediated diseases

Publications (1)

Publication Number	Publication Date
DK0744950T3 true DK0744950T3 (da)	2004-10-25

Family

ID=12141437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95909122T DK0744950T3 (da)	1994-02-22	1995-02-20	Middel til forhindring og behandling af thromboxan A2-medierede sygdomme

Country Status (16)

Country	Link
US (1)	US5798357A (da)
EP (1)	EP0744950B1 (da)
JP (1)	JP3858279B2 (da)
KR (1)	KR100345187B1 (da)
CN (1)	CN1084620C (da)
AT (1)	ATE273708T1 (da)
AU (1)	AU1718395A (da)
CA (1)	CA2183234C (da)
DE (1)	DE69533392T2 (da)
DK (1)	DK0744950T3 (da)
ES (1)	ES2222464T3 (da)
FI (1)	FI116882B (da)
IL (1)	IL112695A (da)
NO (1)	NO311490B1 (da)
WO (1)	WO1995022329A1 (da)
ZA (1)	ZA951470B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW482675B (en) *	1997-01-31	2002-04-11	Green Cross Corp	Compositions for oral administration containing pyridazinone compounds technical field of the invention
DK1025847T3 (da) *	1997-08-28	2006-02-13	Nissan Chemical Ind Ltd	Neovaskulariseringspromotorer og neovaskulariseringsforstarkere
US6143113A (en)	1998-03-02	2000-11-07	Le Groupe Recherche I.D. Inc.	Repulpable corrugated boxboard
RU2229297C2 (ru) *	1998-09-01	2004-05-27	Ниссан Кемикал Индастриз, Лтд.	Терапевтический агент для лечения стеноза позвоночного канала
CA2353956C (en) *	1998-12-07	2008-10-28	Nissan Chemical Industries, Ltd.	Remedial agent for erectile dysfunction
AU2004308806B9 (en) *	2003-12-26	2010-01-28	Nissan Chemical Industries, Ltd.	Neutrophilia inhibitor
WO2009097406A1 (en) *	2008-01-29	2009-08-06	Indigo Pharmaceuticals	A method of administering a pde3 inhibitor via titration for the treatment of peripheral arterial disease
CN113546049B (zh) *	2021-04-30	2023-03-17	贵州汉方药业有限公司	一种柔性丸剂药物黏合剂及使用该黏合剂制成的柔性丸剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4599336A (en) *	1983-08-08	1986-07-08	Hoffmann-La Roche Inc.	Derivatives of (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenamide
EP0142057A3 (en) *	1983-11-04	1988-03-30	F. Hoffmann-La Roche Ag	Thiazoloquinazoline derivatives, their preparation and pharmaceutical compositions containing same
HU198696B (en) *	1987-01-20	1989-11-28	Nissan Chemical Ind Ltd	Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components
JPH02256668A (ja) *	1988-12-20	1990-10-17	Nissan Chem Ind Ltd	ピリダジノン誘導体
ES2149761T3 (es) *	1990-04-25	2000-11-16	Nissan Chemical Ind Ltd	Derivado de piridazinona.

1995
- 1995-02-19 IL IL11269595A patent/IL112695A/xx not_active IP Right Cessation
- 1995-02-20 CN CN95191744A patent/CN1084620C/zh not_active Expired - Lifetime
- 1995-02-20 CA CA002183234A patent/CA2183234C/en not_active Expired - Lifetime
- 1995-02-20 AT AT95909122T patent/ATE273708T1/de active
- 1995-02-20 DE DE69533392T patent/DE69533392T2/de not_active Expired - Lifetime
- 1995-02-20 AU AU17183/95A patent/AU1718395A/en not_active Abandoned
- 1995-02-20 EP EP95909122A patent/EP0744950B1/en not_active Expired - Lifetime
- 1995-02-20 WO PCT/JP1995/000244 patent/WO1995022329A1/en not_active Ceased
- 1995-02-20 ES ES95909122T patent/ES2222464T3/es not_active Expired - Lifetime
- 1995-02-20 KR KR1019960704529A patent/KR100345187B1/ko not_active Expired - Lifetime
- 1995-02-20 US US08/687,604 patent/US5798357A/en not_active Expired - Lifetime
- 1995-02-20 DK DK95909122T patent/DK0744950T3/da active
- 1995-02-21 JP JP03230095A patent/JP3858279B2/ja not_active Expired - Fee Related
- 1995-02-22 ZA ZA951470A patent/ZA951470B/xx unknown
1996
- 1996-08-20 NO NO19963463A patent/NO311490B1/no not_active IP Right Cessation
- 1996-08-21 FI FI963264A patent/FI116882B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATE273708T1 (de)	2004-09-15
JPH07285869A (ja)	1995-10-31
CA2183234A1 (en)	1995-08-24
AU1718395A (en)	1995-09-04
US5798357A (en)	1998-08-25
WO1995022329A1 (en)	1995-08-24
DE69533392D1 (de)	2004-09-23
KR100345187B1 (ko)	2002-12-05
CA2183234C (en)	2004-05-04
EP0744950A1 (en)	1996-12-04
NO311490B1 (no)	2001-12-03
CN1141590A (zh)	1997-01-29
KR970701048A (ko)	1997-03-17
NO963463L (no)	1996-08-20
JP3858279B2 (ja)	2006-12-13
IL112695A (en)	1999-04-11
FI963264A7 (fi)	1996-08-21
FI963264A0 (fi)	1996-08-21
ES2222464T3 (es)	2005-02-01
DE69533392T2 (de)	2005-09-01
IL112695A0 (en)	1995-05-26
FI116882B (fi)	2006-03-31
EP0744950B1 (en)	2004-08-18
CN1084620C (zh)	2002-05-15
ZA951470B (en)	1995-12-07

Publication	Publication Date	Title
ZA951688B (en)	1995-12-11	Aspartyl protease inhibitors
MY136173A (en)	2008-08-29	4-oxoquinoline compound and use thereof as hiv integrase inhibitor
ATE443043T1 (de)	2009-10-15	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
GR3030354T3 (en)	1999-09-30	Substituted arylalkynyl- and heteroarylalkynyl-n-hydroxyurea inhibitors of leukotriene biosynthesis.
GB9408577D0 (en)	1994-06-22	New compound
MY141661A (en)	2010-05-31	17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO305950B1 (no)	1999-08-23	1-amidinofenyl-pyrrolidoner, piperidinoner, azetinoner som plateaggregeringshemmere og farmasoeytiske preparater inneholdende forbindelsene
NZ515567A (en)	2004-03-26	Method for treating chronic pain using MEK inhibitors
PL361404A1 (en)	2004-10-04	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
NZ526913A (en)	2004-12-24	Inhibitors of cruzipain and other cysteine proteases
BRPI0417345A (pt)	2007-03-13	compostos inibidores de quìnase baseados em azola, composições e seus usos
IN2005KO00312A (da)	2015-08-14
AU4888401A (en)	2001-10-23	Sulfonamide derivative as a matrix metalloproteinase inhibitor
DK0752813T3 (da)	2003-01-06	Hæmmere af metozoan-parasit-proteaser
NO963463L (no)	1996-08-20	Middel for profylakse og behandling av tromboksan A2-medierte sykdommer
MX2022013692A (es)	2022-11-30	Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo.
DE60318874D1 (en)	2008-03-13	Pyrazolderivate
ES2125474T3 (es)	1999-03-01	Derivados de piridazinona o sus sales, procedimentos para su produccion y agentes anti-shock que los contienen.
PL313037A1 (en)	1996-05-27	Phenoxphenylocyclopententenylohydroxyureas
AU2003263455A1 (en)	2004-04-19	Pyrazole amides for treating hiv infections
DK0678088T3 (da)	1996-11-18	N-acylpyrrolidiner og lægemidler til behandling og forebyggelse af cholecystokinin- og gastrinrelaterede sygdomme
BR0307266A (pt)	2004-12-07	Compostos que inibem a atividade do fator xa
NZ789736A (en)	2025-10-31	Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome
PT971714E (pt)	2002-12-31	Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
MXPA04005310A (es)	2004-09-13	Inhibidores de fosfolipasa a2 citosolica.